Summary of Product Characteristics
last updated on the eMC:
01/12/2011
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 01/12/2011 and displayed until Current
|
Reasons for adding or updating:
|
-
Introduction of new pack/pack size
|
| Date of revision of text on the SPC: 16-Nov-2010 |
| Legal Category: P |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| Additional pack sizes
|
|
Updated on 02/08/2010 and displayed until 01/12/2011
|
Reasons for adding or updating:
|
-
Change to section 4.1 - Therapeutic indications
-
Change to section 5.2 - Pharmacokinetic Properties
|
| Date of revision of text on the SPC: 29-Oct-2008 |
| Legal Category: GSL |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| ADDITIONAL INFORMATION CHANGE IN 4.1 AND IN 5.2
|
|
Updated on 27/10/2008 and displayed until 02/08/2010
|
Reasons for adding or updating:
|
-
Change to section 5.1 - Pharmacodynamic Properties
|
| Date of revision of text on the SPC: 01-Sep-2008 |
| Legal Category: P |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| On ingestion the suspension reacts with gastric acid to rapidly form a raft of alginic acid gel having a near-neutral pH which floats on the stomach contents effectively impeding gastro-oesophageal reflux for up to 4 hours, and protecting the oesophagus from acid.
|
|
Updated on 06/02/2008 and displayed until 27/10/2008
|
Reasons for adding or updating:
|
-
New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
|
|
